Table 1 Baseline characteristics
Variable | Total (n = 1854) | DLI(n = 340) | Non-DLI(n = 1514) | p value |
|---|---|---|---|---|
Sex: male, n (%) | 1203(64.9%) | 206(60.6%) | 997(65.9%) | 0.066 |
Age, y, mean (SD) | 57.4 ± 11.2 | 57.2 ± 11.0 | 57.5 ± 11.2 | 0.694 |
Comorbidity, n (%) | 976(52.6%) | 183(53.8%) | 7 93(52.4%) | 0.629 |
BMI, mean (SD) | 24.4 ± 3.4 | 24.2 ± 3.4 | 24.4 ± 3.4 | 0.567 |
Previous abdominal operation, n (%) | 361(19.5%) | 76(22.4%) | 285(18.8%) | 0.138 |
Tumor size | 3.6 ± 1.6 | 3.7 ± 1.7 | 3.6 ± 1.6 | 0.526 |
Neoadjuvant chemoradiotherapy, n (%) | 452(24.4%) | 76(22.4%) | 376(24.8%) | 0.335 |
ASA score, n (%) | 0.447 | |||
1 | 139(7.5%) | 28(8.2%) | 111(7.3%) | |
2 | 1480(79.8%) | 272(80.0%) | 1208(79.8%) | |
3 | 232(12.5%) | 40(11.8%) | 192(12.7%) | |
4 | 2(0.1%) | 0(0.0%) | 2(0.1%) | |
5 | 1(0.1%) | 0(0.0%) | 1(0.1%) | |
Histology, n (%) | 0.766 | |||
Adenocarcinoma | 1682(90.7%) | 305(89.7%) | 1377(91.0%) | |
Mucinous adenocarcinoma | 163(8.8%) | 33(9.7%) | 130(8.6%) | |
Signet-ring cell carcinoma | 9(0.5%) | 2(0.6%) | 7(0.5%) | |
Differentiation degree, n (%) | 0.903 | |||
Low | 416(22.4%) | 79(23.2%) | 337(22.3%) | |
Moderate | 1335(72.0%) | 240(70.6%) | 1095(72.3%) | |
High | 103(5.6%) | 21(6.2%) | 82(5.4%) | |
pT category, n (%) | 0.130 | |||
pT0 | 69(3.7%) | 10(2.9%) | 59(3.9%) | |
pT1 | 87(4.7%) | 14(4.1%) | 73(4.8%) | |
pT2 | 590(31.8%) | 105(30.9%) | 485(32.0%) | |
pT3 | 961(51.8%) | 176(51.8%) | 785(51.8%) | |
pT4 | 147(7.9%) | 35(10.3%) | 112(7.4%) | |
pN category, n (%) | 0.087 | |||
pN0 | 1053(56.8%) | 179(52.2%) | 874(57.7%) | |
pN+ | 801(43.2%) | 161(47.4%) | 640(42.3%) | |
Stage, n (%) | 0.073 | |||
0 | 61(3.3%) | 8(2.4%) | 53(3.5%) | |
1 | 513(27.7%) | 87(25.6%) | 426(28.1%) | |
2 | 479(25.8%) | 84(24.7%) | 395(26.1%) | |
3 | 801(43.2%) | 161(47.4%) | 640(42.3%) | |
Lymphovascular invasion, n (%) | 281(15.2%) | 78(22.9%) | 203(13.4%) | <0.001* |
Perineural invasion, n (%) | 365(19.7%) | 98(28.8%) | 267(17.6%) | <0.001* |
Surgical technique, n (%) | 0.559 | |||
Open surgery | 640(34.5%) | 122(35.9%) | 518(34.2%) | |
Laparoscopic surgery | 1214(65.5%) | 218(64.1%) | 996(65.8%) | |
Operative time, min, mean (SD) | 206.1 ± 68.6 | 202.1 ± 65.6 | 207.0 ± 69.3 | 0.233 |
Estimated blood loss, ml, mean (SD) | 204.2 ± 258.5 | 246.5 ± 245.0 | 238.8 ± 261.5 | 0.620 |
Number of lymph nodes examined in the surgery, mean (SD) | 18.7 ± 12.8 | 17.1 ± 9.7 | 19.0 ± 13.4 | 0.015* |
CRM: positive, n (%) | 79(4.3%) | 34(10.0%) | 45(3.0%) | <0.001* |
Adjuvant chemotherapy, n (%) | 0.085 | |||
Yes | 914(49.3%) | 166(48.8%) | 748(49.4%) | |
No | 476(25.7%) | 75(22.1%) | 401(26.5%) | |
NA | 464(25.0%) | 99(29.1%) | 365(24.1%) |